PharmNovo

Executive Summary

PharmNovo is a Swedish private biopharmaceutical company focused on developing novel small molecule therapies for chronic pain, addressing a significant unmet medical need. Founded in 2008 and based in Malmö, the company's lead candidate, PN6047, is a selective NaV1.7 sodium channel blocker designed to treat neuropathic pain without the addictive potential of opioids. Chronic pain affects millions worldwide, and current treatments are often inadequate or carry severe side effects, positioning PharmNovo's approach as a potentially transformative solution. The company is currently in Phase 2 clinical development, working to demonstrate efficacy and safety in patient populations. As a private entity, PharmNovo relies on funding rounds and strategic partnerships to advance its pipeline. With a focused pipeline and a clear target indication, the company represents a compelling opportunity in the pain management space, though clinical and regulatory risks remain.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Top-Line Data for PN604745% success
• Q4 2026Strategic Partnership or Licensing Deal30% success
• TBDSeries C Funding Round60% success